Eli Avisar

3.2k citations
72 papers · 2.2k indexed · h-index 19

Eli Avisar

65 papers receiving 2.1k citations

Peers

Eli Avisar
Comparison fields: 5 of 108
  • Oncology 1.4k
  • Hepatology 385
  • Cancer Research 567
  • Pathology and Forensic Medicine 454
  • Dermatology 183
Replace Peter J. Rosen with:
Peter J. Rosen United States
Anne M. Noonan United States
Hei‐Cheul Jeung South Korea
John Hamm United States
Monika Klinkhammer‐Schalke Germany
Louis A. Leone United States
Cinzia Orlandini Italy
Darren Plant United Kingdom
Riccardo Giampieri Italy
Dieter Koeberle Switzerland
Eli Avisar relative to Peter J. Rosen United States Peter J. Rosen's profile →
Citations per field
00.5×2.9×
Peter J. Rosen · 1×
Citations per year

Countries citing papers authored by Eli Avisar

Since Specialization
Citations

This map shows the geographic impact of Eli Avisar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Avisar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Avisar more than expected).

Fields of papers citing papers by Eli Avisar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Avisar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Avisar. The network helps show where Eli Avisar may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Eli Avisar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eli Avisar Line = papers co-authored together Eli Avisar links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 20240
3 20231
4 202213
5 20225
6 20211
7 20211
8 20215
9 202114
10 202012
11 201721
12 20174
13 20174
14 201521
15 201580
16 2013161
17 20114
18 200966
19 200835
20 200790

About Eli Avisar

Eli Avisar is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Dermatology and Surgery, having authored 72 papers that have together received 2.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (33 papers), Breast Implant and Reconstruction (17 papers), Breast Lesions and Carcinomas (16 papers), Cutaneous Melanoma Detection and Management (10 papers), Global Cancer Incidence and Screening (7 papers), Cancer and Skin Lesions (7 papers), Nonmelanoma Skin Cancer Studies (6 papers) and Lymphatic System and Diseases (5 papers). The work is most often cited by research in Oncology (1.4k citations), Hepatology (385 citations), Cancer Research (567 citations), Pathology and Forensic Medicine (454 citations) and Dermatology (183 citations). Eli Avisar has collaborated with scholars based in United States, Israel and Sweden. Frequent co-authors include Salomone Di Saverio, Juan C. Gutierrez, D. Castaing, F Kunstlinger, S. Giachetti, Françis Lévi, René Adam, Daniel Azoulay, Arié Ariche and Stefan Glück. Their work appears in journals such as Annals of Surgical Oncology, Breast Cancer Research and Treatment, Cancer Research, Journal of Clinical Oncology and The American Journal of Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026